1. Home
  2. TSLX vs ZLAB Comparison

TSLX vs ZLAB Comparison

Compare TSLX & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSLX
  • ZLAB
  • Stock Information
  • Founded
  • TSLX 2010
  • ZLAB 2013
  • Country
  • TSLX United States
  • ZLAB China
  • Employees
  • TSLX N/A
  • ZLAB N/A
  • Industry
  • TSLX Investment Managers
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • TSLX Finance
  • ZLAB Health Care
  • Exchange
  • TSLX Nasdaq
  • ZLAB Nasdaq
  • Market Cap
  • TSLX 1.9B
  • ZLAB 1.8B
  • IPO Year
  • TSLX 2014
  • ZLAB 2017
  • Fundamental
  • Price
  • TSLX $20.40
  • ZLAB $31.38
  • Analyst Decision
  • TSLX Buy
  • ZLAB Strong Buy
  • Analyst Count
  • TSLX 7
  • ZLAB 4
  • Target Price
  • TSLX $22.43
  • ZLAB $52.50
  • AVG Volume (30 Days)
  • TSLX 231.8K
  • ZLAB 976.3K
  • Earning Date
  • TSLX 11-05-2024
  • ZLAB 11-12-2024
  • Dividend Yield
  • TSLX 11.58%
  • ZLAB N/A
  • EPS Growth
  • TSLX 4.41
  • ZLAB N/A
  • EPS
  • TSLX 2.36
  • ZLAB N/A
  • Revenue
  • TSLX $473,575,000.00
  • ZLAB $322,711,000.00
  • Revenue This Year
  • TSLX $10.80
  • ZLAB $48.34
  • Revenue Next Year
  • TSLX N/A
  • ZLAB $47.12
  • P/E Ratio
  • TSLX $8.64
  • ZLAB N/A
  • Revenue Growth
  • TSLX 23.94
  • ZLAB 28.16
  • 52 Week Low
  • TSLX $19.33
  • ZLAB $13.48
  • 52 Week High
  • TSLX $22.35
  • ZLAB $36.60
  • Technical
  • Relative Strength Index (RSI)
  • TSLX 45.10
  • ZLAB 70.41
  • Support Level
  • TSLX $20.33
  • ZLAB $31.52
  • Resistance Level
  • TSLX $20.81
  • ZLAB $36.60
  • Average True Range (ATR)
  • TSLX 0.20
  • ZLAB 1.36
  • MACD
  • TSLX -0.01
  • ZLAB 0.34
  • Stochastic Oscillator
  • TSLX 23.81
  • ZLAB 58.60

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Share on Social Networks: